Covered recipient · General Payments record
JOHN R SCAGNELLI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$57,406.42
310 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,582.50 | 18 |
| Food and Beverage | $5,384.91 | 280 |
| Travel and Lodging | $2,433.12 | 4 |
| Consulting Fee | $673.00 | 3 |
| Education | $332.89 | 5 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 5 of 7; records 201–250 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN R SCAGNELLI
NPI 1437268265 · CMS profile ID 1144624
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
RALEIGH, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 7; records 201–250 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437268265?year=2024&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437268265?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437268265?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOHN R SCAGNELLI, NPI 1437268265, CMS profile ID 1144624, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 310 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437268265?year=2024&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
310 matching records · $57,406.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 310.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $12.49 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135070313 | CMS |
| TG Therapeutics, Inc. | $3,712.50 | 05/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873751 | CMS |
| Mallinckrodt Hospital Products Inc. | $2.76 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132948 | CMS |
| Mallinckrodt Hospital Products Inc. | $6.51 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132952 | CMS |
| UCB, Inc. | $22.77 | 05/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143287981 | CMS |
| EMD Serono, Inc. | $5.27 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120247763 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.18 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118976762 | CMS |
| ANI Pharmaceuticals, Inc. | $16.04 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091164750 | CMS |
| Biogen, Inc. | $7.74 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104829740 | CMS |
| Genentech USA, Inc. | $2,830.00 | 05/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133036067 | CMS |
| Genentech USA, Inc. | $144.89 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133036071 | CMS |
| Genentech USA, Inc. | $31.01 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133036108 | CMS |
| Celgene Corporation | $19.29 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101113016 | CMS |
| EMD Serono, Inc. | $1.26 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120246779 | CMS |
| EMD Serono, Inc. | $1.84 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120247757 | CMS |
| ABBVIE INC. | $28.06 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106028202 | CMS |
| Lilly USA, LLC | $8.12 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135085186 | CMS |
| ABBVIE INC. | $16.26 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106028200 | CMS |
| Biogen, Inc. | $1,614.00 | 04/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104867994 | CMS |
| CSL Behring | $5.90 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134632665 | CMS |
| Alexion Pharmaceuticals, Inc. | $100.00 | 04/19/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094003108 | CMS |
| Celgene Corporation | $20.97 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101113018 | CMS |
| EMD Serono, Inc. | $6.01 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120248305 | CMS |
| Genentech USA, Inc. | $2.61 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133036104 | CMS |
| TG Therapeutics, Inc. | $3,712.50 | 04/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873735 | CMS |
| TG Therapeutics, Inc. | $123.50 | 04/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873763 | CMS |
| TG Therapeutics, Inc. | $440.34 | 04/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873767 | CMS |
| Biogen, Inc. | $269.00 | 04/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104809761 | CMS |
| Biogen, Inc. | $135.00 | 04/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104847454 | CMS |
| Celgene Corporation | $20.50 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101113014 | CMS |
| TG Therapeutics, Inc. | $3.94 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873779 | CMS |
| TG Therapeutics, Inc. | $4.22 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136873805 | CMS |
| Biogen, Inc. | $269.00 | 04/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104818608 | CMS |
| EMD Serono, Inc. | $20.65 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120246483 | CMS |
| Lilly USA, LLC | $18.10 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135070499 | CMS |
| Neurelis, Inc. | $16.51 | 04/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145653591 | CMS |
| Biogen, Inc. | $1,614.00 | 04/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104821998 | CMS |
| Lilly USA, LLC | $11.87 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135060528 | CMS |
| Mallinckrodt Hospital Products Inc. | $1.17 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132939 | CMS |
| Mallinckrodt Hospital Products Inc. | $5.17 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132944 | CMS |
| Lilly USA, LLC | $14.41 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135072331 | CMS |
| Novartis Pharmaceuticals Corporation | $14.35 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087158349 | CMS |
| Merz Pharmaceuticals, LLC | $31.18 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137950586 | CMS |
| Alexion Pharmaceuticals, Inc. | $23.50 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093975585 | CMS |
| Celgene Corporation | $7.01 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101113010 | CMS |
| ANI Pharmaceuticals, Inc. | $19.00 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091150096 | CMS |
| Mallinckrodt Hospital Products Inc. | $5.02 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132931 | CMS |
| Mallinckrodt Hospital Products Inc. | $0.60 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145132935 | CMS |
| Biogen, Inc. | $15.59 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104839160 | CMS |
| PFIZER INC. | $15.23 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130974168 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,477,506.69 | 75 |
| PY2024 | Principal investigator | $1,628,765.17 | 52 |
| PY2023 | Principal investigator | $1,530,243.64 | 74 |
| PY2022 | Principal investigator | $1,263,839.43 | 68 |
| PY2021 | Principal investigator | $893,217.46 | 74 |
| PY2020 | Principal investigator | $963,358.74 | 52 |
| PY2019 | Principal investigator | $1,152,764.37 | 32 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
75 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | TG Therapeutics, Inc. | $800.00 | 12/12/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200221 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,003.60 | 12/09/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200297 |
| Principal investigator 1 | GENZYME CORPORATION | $19,077.00 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130765 |
| Principal investigator 1 | TG Therapeutics, Inc. | $400.00 | 11/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200241 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,601.16 | 11/25/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200293 |
| Principal investigator 1 | GENZYME CORPORATION | $16,984.80 | 11/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130749 |
| Principal investigator 1 | GENZYME CORPORATION | $13,191.30 | 11/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130756 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,900.00 | 11/06/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200305 |
| Principal investigator 1 | TG Therapeutics, Inc. | $600.00 | 11/04/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200301 |
| Principal investigator 1 | TG Therapeutics, Inc. | $250.00 | 11/04/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200303 |
| Principal investigator 1 | TG Therapeutics, Inc. | $21,494.20 | 11/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200295 |
| Principal investigator 1 | Genentech, Inc. | $15,973.00 | 10/28/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624621 |
| Principal investigator 1 | Genentech, Inc. | $4,916.00 | 10/28/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624628 |
| Principal investigator 1 | TG Therapeutics, Inc. | $250.00 | 10/24/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200299 |
| Principal investigator 1 | Genentech, Inc. | $10,298.00 | 10/15/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624625 |
| Principal investigator 1 | ARGENX US, INC. | $5,469.00 | 10/10/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161252 |
| Principal investigator 1 | ARGENX US, INC. | $11,573.00 | 10/10/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161257 |
| Principal investigator 1 | ARGENX US, INC. | $400.00 | 10/08/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161262 |
| Principal investigator 1 | ARGENX US, INC. | $775.00 | 10/08/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161268 |
| Principal investigator 1 | TG Therapeutics, Inc. | $30,534.40 | 09/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200281 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,540.00 | 09/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200287 |
| Principal investigator 1 | GENZYME CORPORATION | $66,390.75 | 09/29/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130681 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 09/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130656 |
| Principal investigator 1 | TG Therapeutics, Inc. | $35,111.40 | 08/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200279 |
| Principal investigator 1 | ARGENX US, INC. | $59.34 | 08/27/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161248 |
| Principal investigator 1 | Genentech, Inc. | $530.00 | 08/26/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624616 |
| Principal investigator 1 | GENZYME CORPORATION | $2,155.00 | 08/25/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130642 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,350.00 | 08/21/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200285 |
| Principal investigator 1 | GENZYME CORPORATION | $13,277.10 | 08/04/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130583 |
| Principal investigator 1 | GENZYME CORPORATION | $8,665.70 | 08/04/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130586 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,736.04 | 08/04/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200291 |
| Principal investigator 1 | TG Therapeutics, Inc. | $14,426.00 | 07/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200277 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,404.64 | 07/29/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200289 |
| Principal investigator 1 | GENZYME CORPORATION | $21,628.00 | 07/28/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130589 |
| Principal investigator 1 | TG Therapeutics, Inc. | $750.00 | 07/22/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200283 |
| Principal investigator 1 | Genentech, Inc. | $15,692.00 | 07/21/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624612 |
| Principal investigator 1 | GENZYME CORPORATION | $15,850.60 | 07/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130551 |
| Principal investigator 1 | Genentech, Inc. | $660.00 | 06/18/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624586 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,000.00 | 06/09/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200267 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,050.00 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200265 |
| Principal investigator 1 | TG Therapeutics, Inc. | $21,322.30 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200263 |
| Principal investigator 1 | GENZYME CORPORATION | $14,570.25 | 05/19/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130448 |
| Principal investigator 1 | GENZYME CORPORATION | $20,802.00 | 05/19/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130467 |
| Principal investigator 1 | Genentech, Inc. | $21,388.00 | 05/09/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624608 |
| Principal investigator 1 | ARGENX US, INC. | $18,238.00 | 05/02/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC | No dispute reported | 06/30/2026 | 1237161245 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,269.76 | 04/24/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200271 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,700.00 | 04/23/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200261 |
| Principal investigator 1 | GENZYME CORPORATION | $31,740.00 | 04/14/2025 | Non-covered Recipient Entity Velocity Clinical Research, Savannah | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148810 |
| Principal investigator 1 | GENZYME CORPORATION | $13,277.10 | 04/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130317 |
| Principal investigator 1 | TG Therapeutics, Inc. | $26,350.00 | 03/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200253 |
| Principal investigator 1 | Genentech, Inc. | $675.00 | 03/26/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624605 |
| Principal investigator 1 | GENZYME CORPORATION | $1,035.00 | 03/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130256 |
| Principal investigator 1 | GENZYME CORPORATION | $15,754.35 | 03/17/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130251 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,700.00 | 03/13/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200275 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,337.20 | 03/10/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200269 |
| Principal investigator 1 | GENZYME CORPORATION | $3,830.00 | 03/04/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130320 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,000.00 | 02/28/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200251 |
| Principal investigator 1 | GENZYME CORPORATION | $5,415.00 | 02/18/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130238 |
| Principal investigator 1 | GENZYME CORPORATION | $7,601.73 | 02/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Savannah | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148806 |
| Principal investigator 1 | Genentech, Inc. | $2,746.00 | 02/18/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624597 |
| Principal investigator 1 | Genentech, Inc. | $65,298.00 | 02/14/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624601 |
| Principal investigator 1 | TG Therapeutics, Inc. | $500.00 | 02/11/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200259 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,000.00 | 01/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200249 |
| Principal investigator 1 | Genentech, Inc. | $380.00 | 01/28/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211624592 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,500.00 | 01/28/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200257 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,078.00 | 01/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190310580 |
| Principal investigator 1 | GENZYME CORPORATION | $19,544.80 | 01/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130308 |
| Principal investigator 1 | GENZYME CORPORATION | $5,769.00 | 01/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130310 |
| Principal investigator 1 | GENZYME CORPORATION | $22,518.00 | 01/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130314 |
| Principal investigator 1 | GENZYME CORPORATION | $7,842.00 | 01/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130328 |
| Principal investigator 1 | GENZYME CORPORATION | $7,465.00 | 01/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226130332 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,900.00 | 01/06/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226200255 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,850.00 | 01/06/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200273 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $274,669.12 | 01/02/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190312271 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $420,174.05 | 01/01/2025 | Non-covered Recipient Entity RALEIGH NEUROLOGY ASSOCIATES | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1190301311 |